An observational study in Breast Cancer, sponsored by Hellenic Cooperative Oncology Group. Active, not recruiting at 1 site in Greece. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Hellenic Cooperative Oncology Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group — 3 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Hellenic Cooperative Oncology Group.
Among the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, this one is the 5th largest by enrollment of the 14 observational ones that give a count, is one of 2 that started in 2013, is one of 14 observational ones, and was the 8th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →3 of the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group are open now, in 1 country. Recruiting first, the newest first:
Hellenic Cooperative Oncology Group · Sites in Greece
Ages 18+
Hellenic Cooperative Oncology Group · Sites in Greece
Ages 18+ · Women only
Hellenic Cooperative Oncology Group · Sites in Greece
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 750 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 82 across the 3 interventional studies, 423 across the 14 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hellenic Cooperative Oncology Group is the lead sponsor of 62 studies on the registry; 6 are open to participants now.
2 of the studies in Breast Neoplasms by Hellenic Cooperative Oncology Group that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04985058Hellenic Cooperative Oncology GroupReal-world Data in Patients With Breast Cancer Treated With Abemaciclib | 2026-11-30 |
| NCT07899463Hellenic Cooperative Oncology GroupESR1 Mutations in Metastatic Hormone Receptor-Positive Breast Cancer in the Greek Population | 2027-05-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a translational study in patients with operated early breast cancer of Luminal A or Luminal B sub types.The Hellenic Cooperative Oncology Group (HeCOG) has designed an observational biomarker-driven study in patients with Luminal A or Luminal B breast cancer, with the aim to collect valuable biological material from these patients and investigate biomarkers with potential prognostic value.
The HE10A/13 study is an observational study of the Hellenic Cooperative Oncology Group (HeCOG). Its main purpose is the collection of biological material from patients in search of prognostic / predictive biomarkers. Each patient signed an informed consent for the provision of biologic material for future research purposes. The study was conducted in accordance with the Declaration of Helsinki. The clinical and translational protocol has been approved by the Hellenic Cooperative Oncology Group Scientific Committee and is under review by the Institutional Review Board of Metropolitan Hospital. Patients exclusively with Luminal A or Luminal B (Estrogen Receptors (ER)-positive with or without Progesterone Receptors (PgR) positive, HER-negative) breast cancer who received adjuvant chemotherapy with positive lymph nodes or node-negative with tumor stage or pathological features according to Saint Gallen guidelines suggesting high-risk or when genomic testing determined in favor of adjuvant chemotherapy are eligible for registration in the study.
Before registration to the study, each patient signed an informed consent for the provision of biologic material for research purposes.
Potential biomarkers will be examined using in situ or molecular methods in Formalin fixed paraffin embedded (FFPE) tumor sections. For tumor subtyping immunohistochemistry for ER, PgR, HER2, Ki67 and Fluorescence in Situ Hybridization (FISH) will be performed where needed for the assessment of HER2 status; for Epidermal Growth Factor Receptor (EGFR) and CK5 for the classification of basal-like tumors; and, the expression of CD8, CD3 and FOXP3 on (Tumor- infiltrating Lymphocytes (TILs) will also be evaluated. Moreover, will be evaluated the mutational profile, including actionable genomic alterations, and the immune response -related profile of Greek women with breast cancer, via the application of DNA/RNA Next Generation Sequencing (NGS) technologies, relative also to patient outcome.
This is a retrospective analysis of patients with operative early breast cancer of Luminal A and Luminal B sub types. Patients have been treated in Hellenic Cooperative Oncology Group (HeCOG) - affiliated departments of Oncology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Patients confirmed with Luminal A breast cancer sub type
Patients confirmed with Luminal B breast cancer sub type
Progression free survival
Time frame: From treatment initiation to the first documented disease progression, up to 5 years
Overall survival
Time frame: From date of treatment initiation until death from any cause or date of last contact whichever occurred first, assessed up to 5 years.
Ran from Apr 2013 to primary completion in Sep 2026, 160 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Dec 2020 → Sep 2026 and completion Mar 2023 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hellenic Cooperative Oncology Group